BioLeonhardt to Present at Cardiac Recovery Symposia @ University of Utah
January 7th, 2016 – Santa Monica, CA – Howard Leonhardt will present the BioLeonhardt Myostim www.bioleonhardt.com stem cell pump + bioelectric stimulator for heart regeneration at the 2016 Cardiac Recovery at the University of Utah School of Medicine. Oral Presentation “Implantable Regeneration Stimulator and Refillable Micro Infusion Pump for 36 Month Total Reversal of Heart Failure” will be 3:45pm Thursday January 14th. A poster will also be presented on the 14th and 15th 12:30pm to 1:30pm.
The BioLeonhardt MyoStim pump+stimulator is implanted in a patient’s abdomen. The micro pump is re-filled once a week with a cardio myogenic and angiogenic cocktail of stem cells, growth factors, micro RNAs, nutrient hydrogel and endocardial matrix. The pump contents are infused slowly into the damaged area of the heart over time via an infustion pacing lead. The bioelectric stimualtor causes controlled release of SDF-1, VEGF, Follistatin and Hepatocyte Growth Factor and controls the differentiation of cells into contractile muscle and mature blood vessels within heart scar tissue. The current translational studies are designed to prove out ability to fully regenerate a damaged heart over a 36 month course of treatment. SDF-1 is a stem cell homing factor, VEGF grows blood vessels, Follistatin grows muscle and Hepatocyte Growth Factor prevents arrhythmias.
A heart regeneration translational study is being launched in Europe led by Dr. Eric Duckers. The clinical plan calls for this pilot study to be followed by a U.S./European/Asian Phase II study with the University of Utah and Ohio State University participating as well as up to 32 additional centers. Dr. William Abraham Chief of Heart Failure at Ohio State University serves as Chairman of the BioLeonhardt Scientific Advisory Board serving along with Dr. Doris Taylor from Director of Regenerative Medicine at Texas Heart Institute and Dr. Jorge Genovese. Dr. Amit Patel from the University of Utah also is a clinical trial design advisor for the planned studies. Dr. Patel and his team at the University of Utah have developed an endocardial matrix (ECM), a natural injectable matrix made up of a mixture of VentriGelTM, a hydrogel derived from scaffolding protein that is extracted naturally from the heart. The BioLeonhardt team intends to load this matrix into its micro infusion pump as one of the more than 15 components utilized in its planned heart regeneration protocol. The Cardiobridgewww.cardiobridge.com Reitan circulatory assist pump will be utilized at periodic intervals during the heart regeneration clinical trial to off load the work requirements of the heart to promote healing and regeneration.
Leonhardt Ventures, the parent of BioLeonhardt MyoStim, and its team of collaborating research scientists have been studying stem cell based regeneration of limbs since 1985 and hearts since 1988 and has helped raise and put to work over $100 million to date for developing heart, cardiovascular and other organ regeneration and healing products.
BioLeonhardt MyoStim is being incubated in the Leonhardt Ventures’ Cal-X Stars Business Accelerator, Inc www.calxstars.com in Santa Monica and Santa Rosa, California.
BioLeonhardt, Leonhardt Ventures’ and the Cal-X Stars Accelerator are led by a team over 70 proven industry veterans- http://calxstars.com/team-cal-x/ and over 35 leading scientists and clinicians on its Scientific Advisory Board – http://calxstars.com/scientific-advisory-board/.
Leonhardt Ventures an Cal-X Stars portfolio technologies include…
MyoStim Pacers – http:/www.myostimpacers.com – heart failure pacemaker designed to recruit reparative stem cells to damaged and weakened heart tissue.
MyoStim Microcurrent Stimulators – Full lineup of microcurrent stimulators for stem cell directed organ regeneration and healing –
http://www.myostimpacers.com/microcurrent-stimulators.php
Bioheart, Inc. – http://www.bioheartinc.com – Phase III leader in applying adult muscle stem cells to treat advanced heart failure since 1999. In the Phase II/III MARVEL randomized, double blinded, placebo controlled study Bioheart’s MyoCell achieved 95.7 meters improvement in exercise capacity over placebo (minus 4 meters). The MARVEL study included 33 leading U.S. heart failure centers (Note - Leonhardt Ventures founded Bioheart, Inc. in 1999 but turned control over to acquirers of the stock following the 2008 NASDAQ IPO).
BioPace – biological pacemaker made entirely of living cells –http://www.leonhardtventures.com/biopace.php
Cardiobridge – http://www.cardiobridge.com – high flow rate 10FR circulatory support catheter pump in clinical testing for acute decompensating heart failure and high-risk PCI. Relieving the heart of work load is being studied to possibly improve stem cell transplantation results. (Note - Cardiobridge is the only startup in this portfolio not founded by Leonhardt Ventures).
Valvublator – heart valve regeneration with stem cell based bioelecric stimulation – http://www.leonhardtventures.com/valbulator.php +www.valvublator.com
AortaCell – Bioelectric stimulation stem cell based aorta regeneration – http://www.leonhardtventures.com/aortacell.php
CerebreCell – Bioelectric stimulation and stem cell infusion for brain regeneration and stroke recovery - http://www.leonhardtventures.com/test.php
HeartScore – www.heartscore.co – precision medicine, functional genomics and tech monitoring platform for reducing hospitalizations from heart failure.
BioLeonhardt MyoStim has begun to develop and file patent applications for a FULL BODY REGENERATION CHAMBER utilizing wireless energy to scan and direct regenerative energy signals (recruits stem cells) to organs in need of regeneration including brain, skin, eyes, liver, kidney, pancreas, heart, joints supplemented when needed with infusions via programmable micro pumps.
For More Scientific Supporting Data Click Here > http://www.bioleonhardt.com/supporting-articles/
About Leonhardt Ventures: Since 1982 Leonhardt Ventures has a strong history of inventing, developing, backing and bringing to market leadership products for treating heart and cardiovascular disease. Over 240,000 patients have been treated to date with Leonhardt inventions. Leonhardt Venture’s started the Cal-X Stars Business Accelerator in 2013 to guide forward cardiovascular and social good impact innovations over a 5 year period.
About Howard Leonhardt: Inventor with over 21 patents for treating cardiovascular disease. Serial entrepreneur founding over 30 startups.
Contact: Howard Leonhardt, Leonhardt Ventures’ Cal-X Stars Business Accelerator, Inc., 1531 6th Street, Unit 401, Santa Monica, California, 90401, Office direct 310 310 2534, Email: hleonhardt@aol.com
SOURCE: Leonhardt Ventures (Leonhardt Vineyards LLC DBA Leonhardt Ventures) & Cal-X Stars Business Accelerator, Inc.
RELATED LINKS
http://www.leonhardtventures.com
www.myostimpacers.com
www.bioleonhardt.com
www.calxstars.com
www.calxcrowdfund.com
www.valvublator.com